EASL 2016: Looking For A Competitive Edge In Hepatitis C
This article was originally published in Scrip
Executive Summary
The International Liver Congress hosted by the European Association of the Study of the Liver (EASL) from April 13 to 17 in Barcelona will give hepatitis C drug developers an opportunity to carve out competitive niches before Phase III data for shorter treatment regimens are revealed later in 2016.
You may also be interested in...
Gilead's Epclusa Approved As First Pan-Genotypic HCV Therapy
Fixed-dose combo of sofosbuvir and velpatasvir is approved to treat genotypes 1-6 and be the first ribavirin-free regimen for genotypes 2 and 3 of the virus.
Sales Down, Discounts Up: Hepatitis C Market Feeling Zepatier Launch
As the third to market, Merck & Co. Inc.'s recently launched Zepatier brought in a modest $50m in sales during the first quarter – but the drug has had an outsized impact on the hepatitis C field, with competitors Gilead Sciences Inc. and AbbVie Inc. both citing the new competition among the reasons for their declining HCV product sales during the first quarter.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.